
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 4 |
| Top 5 Target | Count |
|---|---|
| GSK-3β x PKCα | 1 |
| CA1(Carbonic anhydrase I) | 1 |
| CASP family x PPARγ x RELA | 1 |
| CTNNB(Beta catenins) | 1 |
Target |
Mechanism GSK-3β modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism PPARγ antagonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CTNNB inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2026 |
Sponsor / Collaborator |
Start Date28 Feb 2026 |
Sponsor / Collaborator |
Start Date15 Feb 2026 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Lobaric Acid ( CTNNB ) | Breast Cancer More | Preclinical |
D-carvone ( GSK-3β x PKCα ) | Acute Lung Injury More | Preclinical |
Betulinic acid ( CASP family x PPARγ x RELA ) | Pancreatitis More | Preclinical |
WO2024019685 ( CA1 )Patent Mining | Obesity More | Discovery |





